Keros To Receive Milestone Payment Under License Agreement With Takeda

Realtime	Geld	Brief	Zeit
	25,130	25,540	22:24
	25,000	25,240	22:00

Realtime

Geld

Brief

Zeit

25,130

25,540

22:24

25,000

25,240

22:00

Keros To Receive Milestone Payment Under License Agreement With Takeda

TOKYO (dpa-AFX) - Keros Therapeutics (KROS) announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes. The dosing of the first patient triggers a $10 million milestone payment to Keros under the license agreement with Takeda.

Under the terms of the license agreement with Takeda to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, Keros received a $200 million upfront cash payment in February 2025, and is eligible to receive development, commercial and sales milestones with the potential to exceed $1.1 billion.

For More Such Health News, visit rttnews.com.

Copyright(c) 2025 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

Hensoldt, Renk & Rheinmetall teuer

Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!

Hier klicken

Zeit	Aktuelle Nachrichten
14:36	Keros To Receive Milestone Payment Under License Agreement With Takeda	TOKYO (dpa-AFX) - Keros Therapeutics (KROS) announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very... ► Artikel lesen
14:18	Keros Therapeutics doses first patient in Phase 3 MDS trial
Di	Keros Therapeutics, Inc. - 8-K, Current Report
10.06.	Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
10.06.	Activist investor demands Keros 'aggressively' cut costs just weeks after layoffs

Zeit

Aktuelle Nachrichten

14:36

Keros To Receive Milestone Payment Under License Agreement With Takeda

14:18

Keros Therapeutics doses first patient in Phase 3 MDS trial

Keros Therapeutics, Inc. - 8-K, Current Report

10.06.

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

10.06.

Activist investor demands Keros 'aggressively' cut costs just weeks after layoffs

Zeit	Aktuelle Nachrichten
14:36	Keros To Receive Milestone Payment Under License Agreement With Takeda	TOKYO (dpa-AFX) - Keros Therapeutics (KROS) announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very... ► Artikel lesen
Mo	Takeda to seek approval of new kind of narcolepsy drug after study data
Mo	Takeda stock rises after positive Phase 3 results for narcolepsy drug
Mo	Positive Studiendaten zu Narkolepsie-Mittel beflügeln Takeda-Aktie
Mo	Takeda's narcolepsy programme gets back on track

Zeit

Aktuelle Nachrichten

14:36

Keros To Receive Milestone Payment Under License Agreement With Takeda

Takeda to seek approval of new kind of narcolepsy drug after study data

Takeda stock rises after positive Phase 3 results for narcolepsy drug

Positive Studiendaten zu Narkolepsie-Mittel beflügeln Takeda-Aktie

Takeda's narcolepsy programme gets back on track